Catalyst Wire Dossier Catalyst Wire Dossier

GA101 (obinutuzumab)

obinutuzumab · Genentech
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for GA101 (obinutuzumab), covering 2018-08-13 to 2025-06-10. Get the full timeline:

Most recent: Clinical Trial Update: Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG) [Phase 2]

See pricing